Trial
NCT04199351
Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Amgen
Collaborators
—
Condition
Obesity
Intervention
AMG 171
Why stopped
Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19